Company Overview - ADC Therapeutics SA (ADCT) is a notable stock within the Medical group, which comprises 929 companies and holds the 10 position in the Zacks Sector Rank [2] - The Zacks Rank system focuses on earnings estimates and revisions to identify stocks with improving earnings outlooks, with ADC Therapeutics currently rated 2 (Buy) [3] Performance Analysis - Over the past three months, the Zacks Consensus Estimate for ADCT's full-year earnings has increased by 24.9%, indicating improved analyst sentiment and a more positive earnings outlook [4] - Year-to-date, ADC Therapeutics has returned 6.5%, outperforming the Medical sector's average return of 6% [4] - In comparison to its specific industry, Medical - Biomedical and Genetics, which has gained about 21.1% this year, ADCT is slightly underperforming [6] Industry Context - The Medical - Biomedical and Genetics industry includes 450 stocks and is currently ranked 88 in the Zacks Industry Rank [6] - Another stock, Assertio (ASRT), has significantly outperformed the sector with a year-to-date return of 29.3% and is rated 1 (Strong Buy) [5] - The Medical - Drugs industry, where Assertio belongs, has 141 stocks and has seen a modest increase of 2.9% this year [7]

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. AIM ImmunoTech Inc. (AIM) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.AIM ImmunoTech Inc. is a member of the Medical sector. This group includes 931 individual stocks and currently holds a Zacks Sector Rank ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Neurocrine Biosciences (NBIX) , which belongs to the Zacks Medical - Drugs industry, could be a great candidate to consider.This biopharmaceutical company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 18.64%.For the most recent quarter, Neuro ...

Core Viewpoint - Ardelyx (ARDX) shares experienced a significant increase of 15% to $7.76, reflecting strong investor confidence in the company's financial performance ahead of its fourth-quarter results [1][2] Financial Performance - Ardelyx reported impressive preliminary product revenue figures for 2025, with Ibsrela generating approximately $274 million, a 73% increase from 2024, and Xphozah generating about $104 million [2] - The upcoming quarterly earnings are expected to be $0.02 per share, unchanged from the previous year, with revenues projected at $118.08 million, a 1.7% increase from the year-ago quarter [3] Earnings Estimates - The consensus EPS estimate for Ardelyx has been revised 80% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [4] Industry Comparison - Ardelyx is part of the Zacks Medical - Drugs industry, where another company, Indivior PLC (INDV), saw a 1.3% increase in its stock price but has returned -10.7% over the past month [4] - Indivior's consensus EPS estimate has increased by 10% over the past month to $0.65, reflecting a year-over-year change of +103.1% [5]

Company Overview - Profound Medical (PROF) shares increased by 9.5% to close at $8.34, with trading volume significantly higher than usual, contrasting with a 0.3% loss over the past four weeks [1] - The rise in share price followed the successful treatment of a prostate cancer patient at Mount Sinai Hospital using the TULSA-PRO system, which integrates advanced technologies for treatment [2] Financial Performance - The company is projected to report a quarterly loss of $0.28 per share, reflecting a year-over-year decline of 40%, while revenues are expected to reach $8 million, marking a 91.4% increase from the previous year [3] - The consensus EPS estimate for the upcoming quarter has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] Industry Context - Profound Medical operates within the Zacks Medical - Drugs industry, where Rigel Pharmaceuticals (RIGL) also holds a Zacks Rank of 3 (Hold) and has seen a 3.4% decrease in its share price [4][5] - Rigel's consensus EPS estimate for its upcoming report is $1.17, representing a 46.3% increase from the previous year, with its stock also experiencing a decline of 6.7% over the past month [5]

Core Viewpoint - Ocular Therapeutix's stock experienced a significant increase of 6.1% to $11.07, driven by rising investor confidence in its product pipeline, particularly for Axpaxli, aimed at treating wet age-related macular degeneration [1][2]. Group 1: Stock Performance - The stock's recent gain contrasts with a 27.5% decline over the previous four weeks, indicating a potential turnaround in investor sentiment [1]. - The trading session saw a higher-than-average volume of shares exchanged, suggesting increased market interest [1]. Group 2: Product Pipeline Developments - Ocular Therapeutix plans to submit a new drug application for Axpaxli in Q1 2026, contingent on positive results from the ongoing phase III SOL-1 study [2]. - Axpaxli is also being investigated for other conditions, including diabetic retinopathy and diabetic macular edema, expanding its potential market [2]. Group 3: Financial Expectations - The company is projected to report a quarterly loss of $0.33 per share, reflecting a year-over-year decrease of 13.8% [3]. - Expected revenues for the upcoming quarter are $15.1 million, down 11.6% from the same period last year [3]. Group 4: Earnings Estimate Trends - The consensus EPS estimate for Ocular Therapeutix has remained unchanged over the last 30 days, indicating stability in earnings expectations [4]. - A lack of movement in earnings estimate revisions typically correlates with stock price trends, suggesting that future performance should be monitored closely [4]. Group 5: Industry Context - Ocular Therapeutix holds a Zacks Rank of 3 (Hold), indicating a neutral outlook within the Zacks Medical - Drugs industry [5]. - In comparison, another company in the same industry, Profound Medical, has seen a 9.1% decline in its stock price, highlighting varying performance within the sector [5][6].

Group 1 - Assertio (ASRT) is a stock that has gained about 14% year-to-date, outperforming the average gain of 7% in the Medical group [4] - Assertio is ranked 8 in the Zacks Sector Rank, which evaluates 932 companies within the Medical sector [2] - The Zacks Rank for Assertio is 1 (Strong Buy), indicating a positive earnings outlook with a 6.6% increase in the full-year earnings estimate over the past quarter [3] Group 2 - Assertio belongs to the Medical - Drugs industry, which has 141 stocks and is currently ranked 96 in the Zacks Industry Rank, with an average gain of 1.9% year-to-date [5] - Another outperforming stock in the Medical sector is Butterfly Network, Inc. (BFLY), which has returned 15.8% year-to-date and has a Zacks Rank of 2 (Buy) [4][5] - The Medical Info Systems industry, to which Butterfly Network belongs, has 42 stocks and is currently ranked 168, with a year-to-date gain of 2% [6]

Core Viewpoint - Ardelyx (ARDX) is currently outperforming the Medical sector, with a year-to-date gain of approximately 32.8% compared to the sector's average gain of 7.5% [4]. Company Performance - Ardelyx is ranked 2 (Buy) in the Zacks Rank system, indicating a strong potential for outperforming the market in the near term [3]. - The Zacks Consensus Estimate for Ardelyx's full-year earnings has increased by 1537.5% over the past three months, reflecting improved analyst sentiment and earnings outlook [4]. - Ardelyx belongs to the Medical - Drugs industry, which has 141 individual stocks and is currently ranked 72 in the Zacks Industry Rank [6]. Industry Context - The Medical group, which includes Ardelyx, is currently ranked 5 within the Zacks Sector Rank, indicating a relatively strong position among 16 different groups [2]. - The Medical - Drugs industry has seen an average gain of 4.2% this year, further highlighting Ardelyx's superior performance [6]. - Another notable stock in the Medical sector is Halozyme Therapeutics (HALO), which has returned 7.7% year-to-date and also holds a Zacks Rank of 2 (Buy) [5].

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. AIM ImmunoTech Inc. (AIM) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.AIM ImmunoTech Inc. is one of 932 individual stocks in the Medical sector. Collectively, these com ...

Group 1 - Humacyte, Inc. (HUMA) has gained approximately 12.4% year-to-date, outperforming the average gain of 7.6% for Medical stocks [4] - The Zacks Rank for Humacyte, Inc. is currently 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - The consensus estimate for Humacyte's full-year earnings has increased by 15.9% over the past quarter, reflecting improved analyst sentiment [3] Group 2 - Humacyte, Inc. is part of the Medical - Biomedical and Genetics industry, which has an average gain of 18.6% this year, indicating that HUMA is slightly underperforming its industry [5] - Acrivon Therapeutics, Inc. (ACRV), another Medical stock, has outperformed the sector with a return of 24.9% year-to-date [4] - The Medical - Drugs industry, to which Acrivon belongs, has gained 3.1% this year and is ranked 90 among 141 stocks [6]